A recent meta-analysis demonstrated that P2Y12 inhibitor monotherapy is associated with a reduced risk of myocardial infarction (MI) and a comparable rate of stroke in patients with established atherosclerotic cardiovascular disease (ASCVD) compared to aspirin monotherapy [3]. Here, P2RY12 is linked to myocardial infarction.